Despite this mechanistic similarity, TBL1XR1-RARB-positive APL demonstrates intrinsic resistance to standard differentiating agents, including ATRA, ATO, and the synthetic retinoid tamibarotene (6, 11, 14, 25). This evidence concerns the gene RARB and acute promyelocytic leukemia.